|
1
|
Tan J, Wang D, Tu A, Xu Q, Zhuan L, Wu X, Zhao L, Dong W, Zhang J, Feng Y. CEBPB regulates ERK1/2 activity through SOS1 and contributes to ovarian cancer progression. Med Oncol 2025; 42:242. [PMID: 40483367 PMCID: PMC12145290 DOI: 10.1007/s12032-025-02794-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/18/2025] [Accepted: 05/15/2025] [Indexed: 06/11/2025]
Abstract
Ovarian cancer (OC) is among the most prevalent malignant tumors affecting the female reproductive system. Notably, CEBPB has emerged as a highly promising biomarker, attracting substantial attention for its role in mediating chemotherapy resistance to PARP inhibitors (PARPi). However, the precise mechanism of action of CEBPB in OC remains poorly understood. CCK-8 assays, colony formation assays, transwell assays, and wound healing assays were employed to assess malignant behaviors of OC cells. Flow cytometry was utilized to analyze cell apoptosis and cell cycle progression. qRT-PCR and Western blot analyses were performed to quantify the levels of SOS1 and phosphorylated ERK1/2 (p-ERK1/2). Overexpression of CEBPB enhanced the proliferation, colony formation ability, invasion, migration, and cell cycle progression of SKOV3 and A2780 OC cells, while simultaneously inhibiting their apoptosis. Conversely, knockdown of CEBPB produced opposite effects (p < 0.01). Results from the MAPK Signaling Pathway PCR Array and Western blot analyses indicated that CEBPB increases the expression of SOS1 (p < 0.01). Additionally, dual-luciferase reporter assays demonstrated that CEBPB binds to the promoter sequence of the target gene SOS1. CEBPB knockdown significantly inhibited the malignant behavior of OC cells and reduced the levels of p-ERK1/2, whereas overexpression of SOS1 partially reversed this effect (p < 0.01). In xenograft models, CEBPB activates ERK1/2 via SOS1 upregulation, which subsequently promotes tumor growth and suppresses apoptosis (p < 0.01). CEBPB regulates ERK1/2 activity through SOS1 and contributes to OC progression.
Collapse
Affiliation(s)
- Jiahong Tan
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Daoqi Wang
- Department of Urology, The Second Affiliated Hospital of Kunming Medical University, No.374 Dianmian Avenue, Kunming, 650101, People's Republic of China.
| | - Aiqing Tu
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Qin Xu
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Li Zhuan
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Xiaodie Wu
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Lin Zhao
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Wei Dong
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China.
| | - Jie Zhang
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| | - Yun Feng
- Department of Obstetrics and Gynecology, The First People's Hospital of Yunnan Province, The Affiliated Hospital of Kunming University of Science and Technology, No.157 Jinbi Road, Kunming, 650032, People's Republic of China
| |
Collapse
|
|
2
|
Barth I, Lee H. Nanophotonic sensing and label-free imaging of extracellular vesicles. LIGHT, SCIENCE & APPLICATIONS 2025; 14:177. [PMID: 40295495 PMCID: PMC12037801 DOI: 10.1038/s41377-025-01866-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2025] [Revised: 04/08/2025] [Accepted: 04/10/2025] [Indexed: 04/30/2025]
Abstract
This review examines imaging-based nanophotonic biosensing and interferometric label-free imaging, with a particular focus on vesicle detection. It specifically compares dielectric and plasmonic metasurfaces for label-free protein and extracellular vesicle detection, highlighting their respective advantages and limitations. Key topics include: (i) refractometric sensing principles using resonant dielectric and plasmonic surfaces; (ii) state-of-the-art developments in both plasmonic and dielectric nanostructured resonant surfaces; (iii) a detailed comparison of resonance characteristics, including amplitude, quality factor, and evanescent field enhancement; and (iv) the relationship between sensitivity, near-field enhancement, and analyte overlap in different sensing platforms. The review provides insights into the fundamental differences between plasmonic and dielectric platforms, discussing their fabrication, integration potential, and suitability for various analyte sizes. It aims to offer a unified, application-oriented perspective on the potential of these resonant surfaces for biosensing and imaging, aiming at addressing topics of interest for both photonics experts and potential users of these technologies.
Collapse
Affiliation(s)
- Isabel Barth
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02115, USA.
| | - Hakho Lee
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
- Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02115, USA.
| |
Collapse
|
|
3
|
Wang CW, Srivastava A, Hanson EK, McEntee CR, Nair T, March JC, Whelan RJ. Mapping the Binding Sites of CA125-Specific Antibodies on a Revised Molecular Model of MUC16. Cancers (Basel) 2025; 17:1458. [PMID: 40361385 PMCID: PMC12070838 DOI: 10.3390/cancers17091458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2025] [Revised: 04/21/2025] [Accepted: 04/24/2025] [Indexed: 05/15/2025] Open
Abstract
Background: The ovarian cancer biomarker CA125 is a peptide epitope found in multiple tandem repeat domains of the mucin MUC16. Although efforts have been undertaken to characterize the interaction between CA125 and its clinically used antibodies, the molecular nature of the CA125 epitope(s) remains undefined. A recent revision of the molecular model of MUC16 provides an opportunity to fully characterize the binding between CA125-specific antibodies and the tandem repeat region of MUC16. Objectives: The objective of this study was to characterize the binding between CA125 antibodies and expressed tandem repeat proteins from MUC16 as part of a longer-term effort to identify the CA125 epitopes with amino-acid-level precision. Methods: Sixteen MUC16 tandem repeat proteins were expressed and purified. Protein expression was confirmed with high-resolution mass spectrometry. The binding interaction of each tandem repeat protein with four CA125-antibodies-the two used in the clinical test (OC125 and M11) and two clones defined as OC125-like and M11-like-was measured using indirect enzyme-linked immunosorbent assay (ELISA) and localized surface plasmon resonance (SPR). Results: Whereas M11 was found by ELISA to bind to all 16 tandem repeat proteins tested, OC125 does not bind to 5 of the 16 repeats. The recognition pattern of the antibodies was largely in agreement between ELISA and SPR, and cases in which binding is observed in ELISA but not in SPR can be attributed to insufficient contact time in SPR analysis. Conclusions: It can be inferred that the M11 epitope is present on all tandem repeats tested, whereas the OC125 epitope is present on fewer tandem repeats.
Collapse
Affiliation(s)
| | | | | | | | | | | | - Rebecca J. Whelan
- Department of Chemistry, University of Kansas, Lawrence, KS 66047, USA; (C.-W.W.); (A.S.); (E.K.H.); (C.R.M.); (T.N.); (J.C.M.)
| |
Collapse
|
|
4
|
Song Y, Liu L, Gao J, Wu N, Yin J. Column chart prediction model for ovarian cancer based on serum ovarian tumor related biomarkers and validation. Adv Med Sci 2025; 70:209-218. [PMID: 40068807 DOI: 10.1016/j.advms.2025.03.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 11/21/2024] [Accepted: 03/04/2025] [Indexed: 03/28/2025]
Abstract
PURPOSE The aim was to study the predictive model and validate serum ovarian tumor-related biomarkers for ovarian cancer histograms. METHOD We randomly selected 181 patients with ovarian tumors and 80 healthy individuals who underwent physical examinations from the hospital's medical record information system as the study participants. Clinical data and detection results of ovarian tumor-related markers such as serum carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9), and human epididymal protein (HE4) were collected from all study participants for analysis. RESULT Significant differences were found in serum CEA, CA125, CA19-9, and HE4 levels between healthy controls, benign ovarian tumors, and ovarian cancer (P < 0.05). Dysmenorrhea (present), family history (present), age at menarche, menstrual period, number of pregnancies, natural abortion frequency, number of induced abortions, CEA, CA125, CA19-9, HE4 were all influencing factors for the incidence of ovarian cancer (P < 0.05). The number of induced abortions, CEA, CA125, CA19-9, and HE4 were all independent risk factors for ovarian cancer, while the natural abortion frequency was a protective factor for ovarian cancer (P < 0.05). The constructed column chart prediction model had good discrimination and prediction accuracy for ovarian cancer, good clinical utility, and higher predictive performance for ovarian cancer than traditional ROMA models. CONCLUSION The ovarian cancer column chart prediction model based on serum ovarian tumor related markers has good discrimination and prediction accuracy for ovarian cancer, with high clinical utility. Future research may need to incorporate more serum markers related to ovarian cancer to further improve the performance of predictive models.
Collapse
Affiliation(s)
- Yuting Song
- Department of Nuclear Medicine, Jilin Province FAW General Hospital, Changchun, China.
| | - Libo Liu
- Department of Hematology and Oncology, Jilin Province FAW General Hospital, Changchun, China
| | - Jie Gao
- Department of Ophthalmology, Jilin Province FAW General Hospital, Changchun, China
| | - Naibao Wu
- Department of Nuclear Medicine, Jilin Province FAW General Hospital, Changchun, China
| | - Jiwei Yin
- Department of Nuclear Medicine, Jilin Province FAW General Hospital, Changchun, China
| |
Collapse
|
|
5
|
Wu M, Cai S, Zhu L, Yang D, Huang S, Huang X, Tang Q, Guan Y, Rao S, Zhou J. Diagnostic performance of a modified O-RADS classification system for adnexal lesions incorporating clinical features. Abdom Radiol (NY) 2025; 50:953-965. [PMID: 39164457 DOI: 10.1007/s00261-024-04538-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2024] [Revised: 08/15/2024] [Accepted: 08/15/2024] [Indexed: 08/22/2024]
Abstract
PURPOSE To compare the diagnostic efficacy of the Ovarian-Adnexal Reporting and Data System (O-RADS) MRI score with that of the modified O-RADS score on the basis of a simplified contrast-enhanced (CE) MRI protocol in characterizing adnexal masses with solid tissue. The added value of clinical features was evaluated to improve the ability of the scoring system to classify adnexal masses. METHODS A total of 124 patients with 124 adnexal lesions containing solid tissue were included in this two-center retrospective study. Among them, there were 40 benign lesions (40/124, 32.3%) and 84 were malignant lesions (84/124, 67.7%). Three radiologists independently reviewed the images and assigned the O-RADS MRI score and the modified O-RADS score for each adnexal mass. Histopathology was used as the reference standard. The diagnostic efficacy of the two scoring methods was compared. Univariate and multivariate logistic regression were performed to evaluate the value of significant features in the prediction of malignant tumors. RESULTS The O-RADS MRI score and modified O-RADS score showed sensitivity at 100.0% (95% CI, 95.7-100.0%) and 71.4% (95% CI, 60.5-80.8%), specificity at 12.5% (95% CI, 4.2-26.8%) and 75.0% (95% CI, 58.8-87.3%), respectively. The area under the curve of the modified O-RADS score was higher than the O-RADS score (0.732 [95% CI, 0.645-0.808] vs 0.575 [95% CI, 0.483-0.663]; p < 0.001). Multivariate analysis showed that the modified O-RADS score 4b or 5 combined with patient age > 38.5 years, nullipara, maximum diameter > 40.5 mm and HE4 > 78.9 pmol/L significantly improved the diagnostic efficacy up to 0.954 (95% CI, 0.901-0.984) (p < 0.001). CONCLUSION A modified O-RADS score combined with certain clinical features can significantly improve the diagnostic efficacy in predicting malignant tumors.
Collapse
Affiliation(s)
- Minrong Wu
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Songqi Cai
- Department of Radiology, Zhongshan Hospital, Fudan University, 180 Fenlin Road, Xuhui District, Shanghai, 200032, People's Republic of China
| | - Liuhong Zhu
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Daohui Yang
- Department of Ultrasound, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Shunfa Huang
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Xiaolan Huang
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Qiying Tang
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Yingying Guan
- Department of Pathology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China
| | - Shengxiang Rao
- Department of Radiology, Zhongshan Hospital, Fudan University, 180 Fenlin Road, Xuhui District, Shanghai, 200032, People's Republic of China.
| | - Jianjun Zhou
- Department of Radiology, Zhongshan Hospital (Xiamen), Fudan University, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China.
- Department of Radiology, Zhongshan Hospital, Fudan University, 180 Fenlin Road, Xuhui District, Shanghai, 200032, People's Republic of China.
- Department of Radiology, Xiamen Municipal Clinical Research Center for Medical Imaging, 668 Jinhu Road, Huli District, Xiamen City, 361015, Fujian, People's Republic of China.
| |
Collapse
|
|
6
|
Hamed AM, Ali FAZ, Mohammed AEME, Alrasheedi M, Ragab I, Aldoghaim M, Soliman SS. The ameliorative effect of chrysin on ovarian toxicity caused by methidathion in female rats. Front Mol Biosci 2024; 11:1470711. [PMID: 39669673 PMCID: PMC11635302 DOI: 10.3389/fmolb.2024.1470711] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2024] [Accepted: 11/07/2024] [Indexed: 12/14/2024] Open
Abstract
Introduction: Methidathion (MD) is commonly used in agriculture and has adverse effects on reproduction. Chrysin (CHR) has several advantageous properties, such as anti-inflammatory, anti-cancer, and antioxidant properties. The purpose of the current investigation was to assess CHR's therapeutic efficacy in reducing ovarian toxicity brought on by MD. Methods: Twenty-four female rats were divided into four groups of six animals each. Group 1 served as a control, while group 2 rats received MD (5 mg/kg). Rats in Group 3 received CHR at a dose of 50 mg/kg. Rats in group 4 received treatment with CHR after MD intoxication. Results and Discussion: Our research revealed that MD significantly (p < 0.001) increased the levels of MDA, caspase-3, FSH, LH, CA-125, and TNF-α but significantly (p < 0.001) decreased the levels of SOD, GSH, E2, and progesterone when compared to the control and CHR groups. After receiving CHR therapy, damage induced by MD was significantly (p < 0.001) repaired. Conclusion: This study showed that CHR could mitigate the adverse effects that MD causes to the ovaries by decreasing oxidative stress, inflammation, and apoptosis; improving antioxidant status; and restoring the correct ratio of sex hormones.
Collapse
Affiliation(s)
- Amany M. Hamed
- Chemistry Department, Faculty of Science, Sohag University, Sohag, Egypt
| | - Fatma Abo Zakaib Ali
- Department of Pathology and Clinical Pathology, Faculty of Veterinary Medicine, Sohag University, Sohag, Egypt
| | | | - Muneera Alrasheedi
- Department of Chemistry, College of Science, Qassim University, Buraidah, Saudi Arabia
| | - Islam Ragab
- Department of Chemistry, College of Science, Qassim University, Buraidah, Saudi Arabia
| | - Maryam Aldoghaim
- Department of Chemistry, College of Science, King Faisal University, Al-Ahsa, Saudi Arabia
| | - Safaa S. Soliman
- Department of Zoology, Faculty of Science, Minia University, Minia, Egypt
| |
Collapse
|
|
7
|
Mladenović M, Jarić S, Mundžić M, Pavlović A, Bobrinetskiy I, Knežević NŽ. Biosensors for Cancer Biomarkers Based on Mesoporous Silica Nanoparticles. BIOSENSORS 2024; 14:326. [PMID: 39056602 PMCID: PMC11274377 DOI: 10.3390/bios14070326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/12/2024] [Revised: 06/25/2024] [Accepted: 06/28/2024] [Indexed: 07/28/2024]
Abstract
Mesoporous silica nanoparticles (MSNs) exhibit highly beneficial characteristics for devising efficient biosensors for different analytes. Their unique properties, such as capabilities for stable covalent binding to recognition groups (e.g., antibodies or aptamers) and sensing surfaces, open a plethora of opportunities for biosensor construction. In addition, their structured porosity offers capabilities for entrapping signaling molecules (dyes or electroactive species), which could be released efficiently in response to a desired analyte for effective optical or electrochemical detection. This work offers an overview of recent research studies (in the last five years) that contain MSNs in their optical and electrochemical sensing platforms for the detection of cancer biomarkers, classified by cancer type. In addition, this study provides an overview of cancer biomarkers, as well as electrochemical and optical detection methods in general.
Collapse
Affiliation(s)
| | | | | | | | | | - Nikola Ž. Knežević
- BioSense Institute, University of Novi Sad, Dr Zorana Djindjica 1, 21000 Novi Sad, Serbia; (M.M.); (S.J.); (M.M.); (A.P.)
| |
Collapse
|
|
8
|
Aue-Aungkul A, Muktabhant C, Kleebkaow P. Ovarian tumour-cutaneous fistula as a primary presentation of pelvic malakoplakia coexisting with a benign ovarian tumour mimicking advanced ovarian cancer. BMJ Case Rep 2024; 17:e260990. [PMID: 38914526 DOI: 10.1136/bcr-2024-260990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/26/2024] Open
Abstract
Malakoplakia is a rare granulomatous, chronic inflammatory disease generally affecting the urogenital organs, though it can arise in other organs. The clinical manifestations of malakoplakia vary depending on the affected organ. The final diagnosis is confirmed by the presence of Michaelis-Gutmann bodies on pathology. This report describes a case of pelvic malakoplakia accompanied by an ovarian tumour-cutaneous fistula, initially misdiagnosed as advanced ovarian cancer invading the anterior abdominal wall with left pleural effusion based on imaging studies and increased serum carbohydrate antigen 19-9. The patient underwent left thoracentesis and fluid collection from the fistula tract for cytology, which showed no malignancy. She underwent primary debulking surgery, including removal of the fistula tract from anterior abdominal wall. Histopathological examination revealed malakoplakia coexisting with mucinous cystadenoma of the left ovary. For postoperative management, she received prolonged oral antibiotics for 6 months. There was no evidence of disease recurrence at the 24-month follow-up.
Collapse
Affiliation(s)
- Apiwat Aue-Aungkul
- Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| | | | - Pilaiwan Kleebkaow
- Obstetrics and Gynaecology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
- Pathology, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand
| |
Collapse
|
|
9
|
Yang Q, Zhang H, Ma PQ, Peng B, Yin GT, Zhang NN, Wang HB. Value of ultrasound and magnetic resonance imaging combined with tumor markers in the diagnosis of ovarian tumors. World J Clin Cases 2023; 11:7553-7561. [DOI: 10.12998/wjcc.v11.i31.7553] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/23/2023] [Revised: 09/21/2023] [Accepted: 10/25/2023] [Indexed: 11/06/2023] Open
Abstract
BACKGROUND Compare the diagnostic performance of ultrasound (US), magnetic resonance imaging (MRI), and serum tumor markers alone or in combination for detecting ovarian tumors.
AIM To investigate the diagnostic value of US, MRI combined with tumor markers in ovarian tumors.
METHODS The data of 110 patients with ovarian tumors, confirmed by surgery and pathology, were collected in our hospital from February 2018 to May 2023. The dataset included 60 cases of benign tumors and 50 cases of malignant tumors. Prior to surgery, all patients underwent preoperative US and MRI examinations, as well as serum tumor marker tests [carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4)]. The aim of the study was to compare the diagnostic performance of these three methods individually and in combination for ovarian tumors.
RESULTS This study found statistically significant differences in the ultrasonic imaging characteristics between benign and malignant tumors. These differences include echo characteristics, presence or absence of a capsule, blood flow resistance index, clear tumor shape, and blood flow signal display rate (P < 0.05). The apparent diffusion coefficient values of the solid and cystic parts in benign tumors were found to be higher compared to malignant tumors (P < 0.05). Additionally, the time-intensity curve image features of benign and malignant tumors showed significant statistical differences (P < 0.05). The levels of serum CA125 and HE4 in benign tumors were lower than those in malignant tumors (P < 0.05). The combined use of US, MRI, and tumor markers in the diagnosis of ovarian tumors demonstrates higher accuracy, sensitivity, and specificity compared to using each method individually (P < 0.05).
CONCLUSION US, MRI, and tumor markers each have their own advantages and disadvantages when it comes to diagnosing ovarian tumors. However, by combining these three methods, we can significantly enhance the accuracy of ovarian tumor diagnosis, enabling early detection and identification of the tumor’s nature, and providing valuable guidance for clinical treatment.
Collapse
Affiliation(s)
- Qian Yang
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
- Taihe Hospital of Traditional Chinese Medicine, Fuyang 236000, Anhui Province, China
| | - Hui Zhang
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
| | - Pei-Qi Ma
- Fuyang People’s Hospital, Fuyang 236000, Anhui Province, China
| | - Bin Peng
- Fuyang People’s Hospital, Fuyang 236000, Anhui Province, China
| | - Gui-Tao Yin
- No. 2 People’s Hospital of Fuyang City, Fuyang 236000, Anhui Province, China
| | - Nan-Nan Zhang
- Linquan People’s Hospital, Fuyang 236000, Anhui Province, China
| | - Hai-Bao Wang
- The First Affiliated Hospital of Anhui Medical University, Hefei 230022, Anhui Province, China
| |
Collapse
|
|
10
|
Yang L, Du L, Hou B, Niu X, Wang W, Shen W. Clinical Value of Combined Multi-Indicator Tests in Diagnosis of Benign Ovarian. Int J Gen Med 2023; 16:2047-2053. [PMID: 37275333 PMCID: PMC10237279 DOI: 10.2147/ijgm.s410393] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2023] [Accepted: 05/16/2023] [Indexed: 06/07/2023] Open
Abstract
Background To investigate the existence and degree of correlation between benign ovarian tumors and physiological indicators such as reproductive hormones and tumor markers. Methods A total of 150 patients with benign ovarian tumors admitted to Jiaxing First Hospital between January 1, 2019, and May 30, 2021, were enrolled as research subjects, while 104 healthy women were enrolled in the control group. Comparative analysis of the correlation between the reproductive hormones LH, FSH, T, E2, and the tumor indicators AMH, AFP, CEA, CA125, and CA199 between the groups was performed. Results There was no statistical difference in LH, FSH, T, AMH, and CEA expression levels between the experimental and control groups (p≥0.05); E2, CA125, and CA199 levels were higher significantly in the experimental group than in the control group (P<0.001); AFP levels were significantly lower in the experimental group than in the control group (P<0.05). CA125 (0.762) had the highest AUC when diagnosing the value of each index of E2, CA125, and CA199 for benign ovarian tumors. CA125 had the highest sensitivity (56.7%), followed by E2 (50.0%); CA199 had the highest specificity (84.5%), followed by CA125 (83.7%). The combined diagnosis of benign ovarian tumors was performed using different combinations of the indicators. When the two indicators were combined for diagnosis, the combination of E2 + CA199 had the highest sensitivity (82.6%), whereas the combination of CA125 + CA199 had the largest AUC (0.783) and the highest specificity (86.4%). The combined diagnosis of E2+CA125+CA199 had a higher AUC than the combined diagnosis of the two indicators (0.805), with a sensitivity of 77.2%, and a specificity of 70.9%. Conclusion The most relevant factors for benign ovarian tumors are E2, CA125, and CA199 and the combination of these three indicators has the highest AUC for disease prediction while increasing the detection rate of benign ovarian tumors.
Collapse
Affiliation(s)
- Lunyun Yang
- Department of Laboratory Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People’s Republic of China
| | - Lin Du
- The Third Xiangya Hospital of Central South University, Changsha, 430074, People’s Republic of China
| | - Bailong Hou
- Department of Laboratory Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People’s Republic of China
| | - Xiaoqin Niu
- Department of Laboratory Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People’s Republic of China
| | - Wei Wang
- Department of Laboratory Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People’s Republic of China
| | - Weifeng Shen
- Department of Laboratory Medicine, The Affiliated Hospital of Jiaxing University, Jiaxing, 314000, People’s Republic of China
| |
Collapse
|
|
11
|
Maturen KE, Shampain KL, Roseland ME, Sakala MD, Zhang M, Stein EB. Malignant Epithelial Tumors of the Ovary. Radiol Clin North Am 2023; 61:563-577. [PMID: 37169424 DOI: 10.1016/j.rcl.2023.02.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
Abstract
Epithelial ovarian neoplasms (EON) constitute the majority of ovarian cancers. Among EON, high-grade serous carcinoma (HGSC) is the most common and most likely to present at an advanced stage. Radiologists should recognize the imaging features associated with HGSC, particularly at ultrasound and MR imaging. Computed tomography is used for staging and to direct care pathways. Peritoneal carcinomatosis is common and does not preclude surgical resection. Other less common malignant EON have varied appearances, but share a common correlation between the amount of vascularized solid tissue and the likelihood of malignancy.
Collapse
|
|
12
|
Foda AAM, Atia T, Sakr HI, Abd Elaziz Ahmed Elnaghi K, Abdelhay WM, Enan ET. Clinicopathological Characteristics and Prognosis of Diffuse Large B-Cell Lymphoma in Relation to CA-125 and CA 19-9 Expression. J Evid Based Integr Med 2023; 28:2515690X231198315. [PMID: 37654084 PMCID: PMC10475264 DOI: 10.1177/2515690x231198315] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2023] [Revised: 07/26/2023] [Accepted: 08/02/2023] [Indexed: 09/02/2023] Open
Abstract
Background: Some epithelial tumors express the carbohydrate antigen 125 (Cancer antigen-125, CA-125) and CA 19-9, especially ovarian and pancreatic tumors. Patients with non-Hodgkin lymphoma (NHL) were reported to have a close association between serum CA-125 levels and adverse prognostic factors with worse survival. We aimed to investigate CA-125 and 19-9 expression in nodal diffuse large B-cell lymphoma, not otherwise specified (DLBCL NOS) tissues using immunohistochemistry (IHC) and their relations to clinicopathological manifestations and patients' survival. Methods: 65 cases of DLBCL NOS were examined. A modified mechanical pencil tip was used to construct Manual Tissue Micro-array (TMA) blocks. Immunohistochemical staining for CA-125 and CA 19-9 was performed and scored semi-quantitatively. All relations were analyzed using established statistical methodologies. Results: Aberrant expression of CA 19-9 was detected in 12% of cases without any expression of CA-125. Moreover, 75% of the CA 19-9 positive cases were statistically significantly associated with anemia and performance status 1. Also, 75% of the CA 19-9 positive cases were females. Conclusions: CA 19-9 was aberrantly expressed in 12% of nodal DLBCL NOS cases and significantly related to anaemia and performance status but not to survival. In cases of DLBCL NOS, CA 19-9 expression cannot be considered an independent prognostic factor. CA-125 was not expressed in nodal DLBCL NOS tissues, necessitating re-evaluation studies. Therefore, it is advised to conduct more research to clarify the potential correlation between serum and tissue CA 19-9 levels and other clinic-pathological characteristics of nodal and extranodal DLBCL NOS patients.
Collapse
Affiliation(s)
- Abd AlRahman Mohammad Foda
- Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
- Pathology Department, General Medicine Practice, Batterjee Medical College, Jeddah, Saudi Arabia
| | - Tarek Atia
- Department of Histology and Cytology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
- Department of Medical Laboratory Sciences, College of Applied Medical Sciences, Prince Sattam Bin Abdulaziz University, Al-Kharj, Saudi Arabia
| | - Hader I. Sakr
- Department of Medical Physiology, Faculty of Medicine, Cairo University, Cairo, Egypt
- Department of Medical Physiology, Medicine Program, Batterjee Medical College, Jeddah, Saudi Arabia
| | - Khaled Abd Elaziz Ahmed Elnaghi
- Oncology Centre, Medical Oncology unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
- Medical Oncology Unit, Oncology Center, Mansoura University, Mansoura, Egypt
| | - Wagih M. Abdelhay
- Department of Histology and Cytology, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
| | - Eman T. Enan
- Pathology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
| |
Collapse
|
|
13
|
Matsutani H, Nakai G, Fujiwara S, Takahashi S, Yamamoto K, Ohmichi M, Osuga K. Frequency of thoracic recurrence based on pathological features in patients with ovarian epithelial tumors in stage I versus higher stages. Jpn J Radiol 2022; 41:500-509. [PMID: 36575285 PMCID: PMC10147781 DOI: 10.1007/s11604-022-01374-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2022] [Accepted: 12/08/2022] [Indexed: 12/29/2022]
Abstract
PURPOSE The aim of this study was to clarify the frequency of thoracic recurrence and identify associated pathological features in postoperative patients with borderline or malignant ovarian epithelial tumors (BMOT) in stage I versus higher stages. MATERIALS AND METHODS A total of 368 consecutive patients with a single primary BMOT were treated at our hospital. This study included the 217 patients with no residual disease on the first CT after standard treatment. The timing and pattern of recurrence on follow-up CT images with a scan range from chest to pelvis were evaluated retrospectively. Patient characteristics, tumor histology, and stage were recorded from electronic medical records. RESULTS After a median follow-up period of 48 months, recurrence was detected by CT in 9 patients in stage I (n = 159) and 15 in stage II/III (n = 58) (p = 0.0001). Thoracic recurrence was detected in four patients in stage I and four in stage II/III (p = 0.15). Abdominal recurrence was identified as a factor associated with thoracic recurrence (P < 0.001). Clear cell carcinomas accounted for three out of four thoracic recurrences in stage I and two out of four in stage II/III, and had the highest rates of thoracic recurrence (7.7% in stage I and 22.2% in stage II/III) among all histological types associated with thoracic recurrence. Among patients with recurrence, thoracic recurrence-free probability (p = 0.38), median abdominal recurrence-free interval (18 vs 16 months; p = 0.55) and thoracic recurrence-free interval (16.5 vs 23 months; p = 0.89) did not differ significantly between stage I and stage II/III. CONCLUSION The frequency and timing of thoracic recurrence did not differ significantly in postoperative patients with BMOT in stage I versus stage II/III. Abdominal recurrence and a histological type of clear cell carcinoma were most often associated with thoracic recurrence in stage I.
Collapse
Affiliation(s)
- Hiroki Matsutani
- Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan.
| | - Go Nakai
- Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan
| | - Satoe Fujiwara
- Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan
| | - Satoru Takahashi
- Department of Radiology, Takatsuki General Hospital, 1-3-13 Kosobecho, Takatsuki, Osaka, 567-1192, Japan
| | - Kazuhiro Yamamoto
- Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan
| | - Masahide Ohmichi
- Department of Obstetrics and Gynecology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan
| | - Keigo Osuga
- Department of Diagnostic Radiology, Osaka Medical and Pharmaceutical University, 2-7 Daigaku-Machi, Takatsuki, Osaka, 569-8686, Japan
| |
Collapse
|
|
14
|
Shin KH, Kim HH, Yoon HJ, Kim ET, Suh DS, Kim KH. The Discrepancy between Preoperative Tumor Markers and Imaging Outcomes in Predicting Ovarian Malignancy. Cancers (Basel) 2022; 14:cancers14235821. [PMID: 36497302 PMCID: PMC9737674 DOI: 10.3390/cancers14235821] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2022] [Revised: 11/18/2022] [Accepted: 11/22/2022] [Indexed: 11/29/2022] Open
Abstract
Preoperative tumor markers and imaging often differ in predicting whether an ovarian tumor is malignant. Therefore, we evaluated the correlation between the predictive values of imaging and tumor markers for diagnosing ovarian tumors, especially when there were discrepancies between the two. We enrolled 1047 patients with ovarian tumors. The predictive values and concordance rates between the preoperative risk of ovarian malignancy algorithm (ROMA) and imaging, including CT and MRI, were evaluated. Diagnoses of 561 CT (77.9%) and 322 MRI group (69.2%) participants were consistent with the ROMA. Among them, 96.4% of the CT (541/561) and 92.5% of the MRI (298/322) group predicted an accurate diagnosis. In contrast, 67.3% (101/150) of CT and 75.2% (100/133) of MRI cases accurately predicted the diagnosis in cases with discrepancies between ROMA and CT or MRI; a total of 32% (48/150) of the CT and 25.5% (34/133) of the MRI group showed an accurate ROMA diagnosis in cases with discrepancies between ROMA and imaging. In the event of a discrepancy between ROMA and imaging when ovarian tumor malignancy prediction, the question is which method should take precedence. This study demonstrates that MRI has the greatest diagnostic accuracy, followed by CT and ROMA. It is also important to understand underlying diseases and benign conditions and rare histopathologies of malignant tumors.
Collapse
Affiliation(s)
- Kyung-Hwa Shin
- Department of Laboratory Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
| | - Hyung-Hoi Kim
- Department of Laboratory Medicine, Pusan National University School of Medicine, Busan 49241, Republic of Korea
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
| | - Hyung Joon Yoon
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
- Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan 49241, Republic of Korea
| | - Eun Taeg Kim
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
- Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan 49241, Republic of Korea
| | - Dong Soo Suh
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
- Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan 49241, Republic of Korea
| | - Ki Hyung Kim
- Biomedical Research Institute, Pusan National University Hospital, Busan 49241, Republic of Korea
- Department of Obstetrics and Gynecology, Pusan National University School of Medicine, Busan 49241, Republic of Korea
- Correspondence:
| |
Collapse
|
|
15
|
Imaging of Metastatic Disease to the Ovary/Adnexa. Magn Reson Imaging Clin N Am 2022; 31:93-107. [DOI: 10.1016/j.mric.2022.06.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|